We tested CAR-T efficacy in 6 prostate PDX models of varied 1 and 2+ cell surface STEAP2 expression levels by IHC, and in every model, dose-dependent tumor growth inhibition and/or regression (Figure 6D), with accompanying IFN-γ release (Figure 6E), was achieved without signs of toxicity as assessed by body weight. Here, STEAP2 is linked to neoplasm.